TELA Bio, Inc. (TELA)
| Market Cap | 213.60M |
| Revenue (ttm) | 17.41M |
| Net Income (ttm) | -28.48M |
| Shares Out | 14.42M |
| EPS (ttm) | -2.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $14.80 |
| Previous Close | $14.57 |
| Change ($) | 0.23 |
| Change (%) | 1.58% |
| Day's Open | 14.34 |
| Day's Range | 14.00 - 14.80 |
| Day's Volume | 19,365 |
| 52-Week Range | 5.39 - 22.61 |
MALVERN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new categ...
Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options
MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue r...
TELA Bio, Inc. (TELA) CEO Tony Koblish on Q3 2020 Results - Earnings Call Transcript
Shares of TELA Bio (NASDAQ:TELA) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 97.65% over the past year to ($0.53), whic...
MALVERN, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue r...
MALVERN, Pa., Nov. 9, 2020 /PRNewswire/ -- TELA Bio, Inc. ("TELA"), an innovative medtech company focused on solving the unmet needs in soft-tissue reconstruction, announced today that it will...
MALVERN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new c...
MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissu...
MALVERN, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissu...
TELA Bio, Inc. (TELA) CEO Tony Koblish on Q2 2020 Results - Earnings Call Transcript
MALVERN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new cat...
MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new...
MALVERN, Pa., July 09, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue...
MALVERN, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue...
MALVERN, Pa., June 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue...
MALVERN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue...
MALVERN, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
MALVERN, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
TELA Bio, Inc. (TELA) CEO Antony Koblish on Q1 2020 Results - Earnings Call Transcript
MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cate...
MALVERN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a ne...
TELA Bio, Inc. (TELA) CEO Antony Koblish on Q4 2019 Results - Earnings Call Transcript
MALVERN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
MALVERN, Pa., Jan. 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
MALVERN, Pa., Jan. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
MALVERN, Pa., Dec. 06, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new cat...
About TELA
TELA Bio, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen... [Read more...]
| Industry Medical Devices | IPO Date Nov 8, 2019 |
| CEO Antony Koblish | Employees 89 |
| Stock Exchange NASDAQ | Ticker Symbol TELA |
Financial Performance
In 2019, TELA Bio's revenue was $15.45 million, an increase of 86.68% compared to the previous year's $8.27 million. Losses were -$22.43 million, 6.32% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for TELA Bio stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 35.14% from the latest price.